USANA Health Sciences (NYSE:USNA) Insider Brent Neidig Sells 5,002 Shares

USANA Health Sciences, Inc. (NYSE:USNA) insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

USANA Health Sciences Price Performance

Shares of NYSE USNA opened at $19.00 on Friday. The stock’s 50-day moving average is $18.75 and its two-hundred day moving average is $19.41. The company has a market cap of $350.74 million, a price-to-earnings ratio of 40.43, a price-to-earnings-growth ratio of 0.72 and a beta of 0.76. USANA Health Sciences, Inc. has a 1-year low of $16.60 and a 1-year high of $38.32.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.17. The company had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Equities research analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

USNA has been the subject of several research reports. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, USANA Health Sciences currently has an average rating of “Reduce”.

Institutional Trading of USANA Health Sciences

Institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue grew its stake in USANA Health Sciences by 8.5% during the 4th quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company’s stock worth $130,000 after buying an additional 525 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in USANA Health Sciences by 4.6% in the fourth quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after purchasing an additional 542 shares during the period. Quantbot Technologies LP increased its stake in USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after buying an additional 646 shares during the period. Intech Investment Management LLC increased its stake in shares of USANA Health Sciences by 13.5% during the third quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after acquiring an additional 918 shares during the period. Finally, National Bank of Canada FI raised its stake in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after buying an additional 1,201 shares in the last quarter. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.